A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Combination Product: LVGN6051 Monoclonal Antibody Injection+toripalimab Injection+paclitaxel Injection Sponsors: Lyvgen Biopharma Holdings Limited Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | HNSCC | Research | Skin Cancer | Squamous Cell Carcinoma | Study